Search / Trial NCT00001007

A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of December 05, 2024

Completed

Keywords

Pregnancy Pregnancy Complications, Infectious Infant, Newborn, Diseases Infusions, Intravenous Drug Evaluation Administration, Oral Acquired Immunodeficiency Syndrome Zidovudine

ClinConnect Summary

Of a total of 908 pediatric AIDS cases, 78 percent have acquired HIV infection from a mother with HIV infection or at high risk for acquisition of HIV, and the number of cases in children is expected to increase over the next several years. AZT therapy may be effective in altering the course of the disease and decreasing the high mortality in these children. It is also possible that early intervention with AZT may prevent the establishment of HIV contracted before, during, or just after birth.

The children entered in this study receive oral and IV AZT. The first 6 children receive 2 IV dos...

Gender

ALL

Eligibility criteria

  • • Inclusion Criteria
  • • Infant gestation period must have been = or \> 36 weeks and birthweight must = or \> 2000 grams. Active infection must not be present at the time of entry into the study although an HIV culture or P24 serum antigen determination must be obtained prior to study entry. The child must have a life expectancy greater than 3 months. Parents or guardian must be available to give informed consent.
  • Prior Medication:
  • Allowed on a case-by-case basis:
  • • Some essential supportive therapies including antibiotics.
  • • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following conditions or symptoms are excluded:
  • • Any of the following laboratory findings within 2 weeks of study entry.
  • • A total bilirubin \> 2 times age-adjusted upper limit of normal.
  • • Liver transaminase values \> 3 x upper limit of normal.
  • • Serum creatinine \> 1.5 x upper limit of normal.
  • • Total granulocyte count \< 1500 cells/mm3.
  • • Hemoglobin \< 10 g/dl or hemoglobinopathy.
  • • A urine toxicology screen positive for any drug or chemical.
  • • Infants must not have hemoglobinopathy or active infection at entry.
  • Prior Medication:
  • Excluded within 2 months of study entry:
  • • Antiretroviral agents.
  • * Excluded within 4 weeks of study entry:
  • • Immunomodulating agents including steroids, interferon, isoprinosine, and interleukin.
  • • Immunoglobulin.
  • * Excluded within 2 weeks of study entry:
  • • Any other experimental therapy, drugs which cause prolonged neutropenia or significant nephrotoxicity, or rifampin / rifampin derivatives.
  • • Some essential supportive therapies including antibiotics may have infrequent or transient effects. These drugs will be considered on a case-by-case basis.
  • Prior Treatment:
  • Excluded within 2 weeks of study entry:
  • • Red blood cells or whole blood transfusion.
  • * Excluded within 4 weeks of study entry:
  • • Lymphocyte transfusions for immune reconstitution.
  • • Infants may not be entered into the study during the first 2 weeks of life if their mother received methadone therapy during the last trimester of her pregnancy or used any known illicit drug. A maternal urine toxicology screen may be optionally performed prior to entry of the child, and children whose mothers have a screen which is positive for any drugs or chemicals may not be enrolled within 2 weeks of the positive screen.

Trial Officials

Modlin J

Study Chair

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Birmingham, Alabama, United States

Baltimore, Maryland, United States

Durham, North Carolina, United States

Baltimore, Maryland, United States

Stanford, California, United States

Boston, Massachusetts, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials